高敏肌钙蛋白I与T变异的方法学评价及临床解读再评估
本文重新审视高敏心肌肌钙蛋白(hs-cTnI和hs-cTnT)检测的分析不精密度对非ST段抬高型心肌梗死(NSTEMI)诊断的影响,比较了基于分析性能规格(APS)与基于参考变化值(RCV)两种方法学理念的差异,强调诊断急性心肌梗死需结合生物标志物变化与临床缺血证据、心电图及影像学,并指出人工智能模型结合hs-cTn可提高诊断准确性。
要点
- hs-cTn检测在诊断阈值相关浓度通常达到≤10% CV,推荐RCV>30%定义有临床意义的变化。
- RCV方法基于个体内生物学变异,个体指数约0.3,支持肌钙蛋白反映生理性心肌细胞 turnover。
- 急性心肌梗死诊断需整合生物标志物变化与临床缺血证据、心电图和影像学发现。
核心结论
- hs-cTnI和hs-cTnT的分析不精密度对NSTEMI诊断的影响需结合方法学差异解读,APS与RCV两种方法各有侧重。
- 急性心肌梗死诊断不能仅依赖生物标志物变化,必须整合临床缺血证据、心电图和影像学。
- 结合hs-cTn与临床变量的人工智能模型可进一步提高诊断准确性。
研究设计与样本
- 本文为观点性论文(opinion paper),旨在突出两种方法学方法之间的概念差异。
- 引用意大利心脏生物标志物研究组的证据及van Schrojenstein Lantman等人的研究进行比较分析。
主要发现
- hs-cTn检测在诊断阈值相关浓度通常达到≤10% CV。
- 推荐参考变化值(RCV)>30%用于定义有临床意义的变化。
- RCV方法基于个体内生物学变异,个体指数约0.3,且该变异持续较低。
- APS受检测特征和临床情境双重影响。
关键数值与推荐
- 2020年ESC指南提出基于绝对delta阈值的快速纳入/排除算法用于急诊科NSTEMI诊断。
- AACC/IFCC共识指南和第四版心肌梗死全球定义强调在99百分位参考上限处的精密度及生物标志物变化的临床意义。
- RCV>30%用于定义有临床意义的变化。
- hs-cTn检测在诊断阈值相关浓度通常达到≤10% CV。
临床怎么用
- 临床解读hs-cTn变化时应结合检测方法学特征和临床情境,而非仅依赖单一阈值。
- 诊断急性心肌梗死需整合生物标志物变化、临床缺血证据、心电图和影像学发现。
- 可考虑结合hs-cTn与临床变量的人工智能模型以提高诊断准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent debates have focused on the impact of analytical imprecision in high-sensitivity cardiac troponin (hs-cTnI and hs-cTnT) assays on the diagnosis of non-ST-elevation myocardial infarction (NSTEMI), based on the absolute delta thresholds for the rapid rule-in/rule-out algorithms in emergency department (ED) according to the 2020 ESC guidelines. Consensus guidelines by the AACC/IFCC and the Fourth Universal Definition of Myocardial Infarction emphasize precision at the 99th percentile upper reference limit and the clinical significance of biomarker changes. Evidence from the Italian Study Group on Cardiac Biomarkers demonstrates that hs-cTn assays generally achieve ≤10 % CV at concentrations relevant to diagnostic thresholds, and recommends a Reference Change Value (RCV) >30 % to define clinically meaningful variation. Conversely, van Schrojenstein Lantman et al. aimed to define the assay performance specifications (APS) required to reliably detect the recommended absolute delta thresholds and the consequences of failure to meet these APS. The aim of this opinion paper is to highlight the methodological and conceptual differences between these two approaches. More specifically, while APS are influenced by both assay characteristics and clinical context, the RCV approach is based on the intra-individual biological variation that remains consistently low (individual index ≈0.3), supporting the interpretation of circulating troponins as markers of physiological cardiomyocyte turnover. Ultimately, diagnosis of acute myocardial infarction requires integration of biomarker changes with clinical evidence of ischemia, ECG, and imaging findings. Emerging artificial intelligence-based models that combine hs-cTn with clinical variables further improve diagnostic accuracy, underscoring the importance of contextual interpretation and paving the way toward personalized medicine in the management of suspected NSTE-ACS.
引用
- Clerico A, Zaninotto M, Plebani M, et al. Methodological evaluation and clinical interpretation of hs-cTnI and hs-cTnT variations: a reappraisal. Clin Chem Lab Med. 2025. PMID: 41139936. doi:10.1515/cclm-2025-1318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。